



Adherium Partners with NuvoAir Medical to Enhance Patient Outcomes

Melbourne, Australia – 10 January 2024: Adherium Limited (ASX:ADR) a leader in digital health technologies, is excited to announce an agreement with NuvoAir Medical, a value-based specialty management platform focused on cardiopulmonary conditions headquartered in Boston, Massachusetts. This agreement has now commenced, which requires NuvoAir to purchase a minimum of 1,000 next generation Hailie® Smartinhaler® sensors, marking another stride in Adherium's rapid commercial expansion strategy in the US.

Adherium's CEO, Rick Legleiter, emphasised the importance of this new customer within the context of the Company's business by commenting, "This partnership signifies another step forward in Adherium's accelerated rollout of our commercial strategy with another significant partner in the United States in addition to Allergy Partners and SENTA, showcasing the growing recognition of the value our digital technology brings to respiratory healthcare."

The advanced features of the next generation Hailie Smartinhalers focus on physiological data capture, including inhalation flow rate and inhalation duration alongside medication adherence monitoring. This is an important step in assisting asthma and COPD sufferers with increased support with their medication usage and disease management. Hailie is the only US FDA 510(k) cleared, drug-agnostic digital Smartinhaler available today providing insights on patient inhaler technique.

ENDS-

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries:
Rick Legleiter
CEO
Adherium Limited
investors@adherium.com

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>

About the Hailie Platform

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease. Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study. The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.

Refer to Adherium's website for references to independent studies: <https://www.adherium.com/our-technology/>.